triazolam has been researched along with Kidney Failure, Chronic in 4 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case of repetitive hallucinations during treatment with a therapeutic dosage of triazolam (0." | 7.69 | Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin. ( Kaneko, S; Kondo, T; Mihara, K; Morita, S; Otani, K; Tokinaga, N, 1996) |
| "A case of repetitive hallucinations during treatment with a therapeutic dosage of triazolam (0." | 3.69 | Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin. ( Kaneko, S; Kondo, T; Mihara, K; Morita, S; Otani, K; Tokinaga, N, 1996) |
| "Six patients with chronic renal failure requiring hemodialysis and ten normal, control subjects." | 2.67 | Impaired ventilatory response to carbon dioxide in patients with chronic renal failure: implications for the intensive care unit. ( Burgess, EE; Burgess, KR; Whitelaw, WA, 1994) |
| "Triazolam 0." | 1.27 | Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics. ( Juhl, RP; Kroboth, PD; Puschett, JB; Rault, R; Silver, MR; Smith, RB; Sorkin, MI, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burgess, KR | 1 |
| Burgess, EE | 1 |
| Whitelaw, WA | 1 |
| Tokinaga, N | 1 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Otani, K | 1 |
| Mihara, K | 1 |
| Morita, S | 1 |
| Kroboth, PD | 1 |
| Smith, RB | 1 |
| Silver, MR | 1 |
| Rault, R | 1 |
| Sorkin, MI | 1 |
| Puschett, JB | 1 |
| Juhl, RP | 1 |
| Berlin, RM | 1 |
1 trial available for triazolam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Impaired ventilatory response to carbon dioxide in patients with chronic renal failure: implications for the intensive care unit.
Topics: Adolescent; Adult; Carbon Dioxide; Female; Humans; Kidney Failure, Chronic; Male; Meperidine; Prospe | 1994 |
3 other studies available for triazolam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin.
Topics: Anti-Anxiety Agents; Drug Therapy, Combination; Erythromycin; Hallucinations; Humans; Kidney Failure | 1996 |
Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
Topics: Adolescent; Adult; Aged; Aluminum Hydroxide; Anti-Anxiety Agents; Humans; Hydrogen-Ion Concentration | 1985 |
Hypnotics in renal failure.
Topics: Benzodiazepines; Flurazepam; Humans; Kidney Failure, Chronic; Triazolam | 1986 |